Phibro Animal Health Corporation
PAHCHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 26, 2026
Scan Results
Daily timeframePhibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company carries a $1.58B market cap, placing it firmly in the small-cap category. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
Market Cap
$1.58B
Beta
0.42
P/E (TTM)
15.97
P/E (Fwd)
10.08
EPS (TTM)
$2.43
EPS (Fwd)
$3.85
ROE
29.7%
ROA
8.5%
Cash
$84.0M
Total Debt
$795.6M
Free CF
-$19.3M
52W Change
-7.0%
Annual Financials
Cash vs Debt
Where PAHC stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, PAHC finished 0.33% below its 150-day moving average ($39.47) and 4.17% below its 200-day moving average ($41.05). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PAHC overbought or oversold?
At the October 20, 2026 close, PAHC's RSI(14) was 72.2, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, PAHC has $84.0M in cash with $795.6M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$19.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at 29.7%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $942.3M (2022) to $1.52B (2026), reflecting a 61% increase over the period.
With a beta below 0.7, Phibro Animal Health Corporation typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Phibro Animal Health Corporation and its sector.